Colin Hill co-founded GNS Healthcare in 2000 and has served as CEO since then. He brings years of hands-on scientific experience to his role, with expertise in the areas of computational physics, artificial intelligence, and personalized medicine. He serves as Chairman of Via Science, a leading big data analytics company focused on the Internet of Things, business intelligence, and finance . He was also a founding member of the Board of Directors of AesRx, a biopharmaceutical company dedicated to the development of new treatment for sickle cell disease (acquired by Baxter in 2014). Colin was the founding chairman of O’Reilly Media’s Strata Rx, the first healthcare big data conference.
In 2004, Colin was named to MIT Technology Review’s TR100 list of the top innovators in the world under the age of 35. He is a frequent speaker at national and international scientific and industry conferences and has been quoted in in numerous publications and television programs, including The Wall Street Journal, CNBC Morning Call, Nature, Forbes, Wired, and The Economist. He graduated from Virginia Tech with a degree in physics and earned masters degrees in physics from both McGill University and Cornell University.
Dr. Khalil is a technology entrepreneur and physicist with a vision of transforming medicine into a discipline that is quantitative, predictive, and patient-‐centric via big data analytic approaches. She co-‐founded two big data companies, Via Science and GNS Healthcare, and is the co-‐inventor of the proprietary computational engine that underpins both entities. She trained in theoretical physics at Cornell University, and has more than 11 years of experience in “big data” analytics for healthcare, medicine, and the life sciences.
She has led several key foundational collaborations with providers, pharmaceutical companies, foundations, and government agencies. Dr. Khalil’s expertise spans applications in drug discovery, drug development all the way to treatment algorithms that can be applied at the point of care. She is a frequent speaker at industry events and conferences, has appeared in several industry journals, published several articles in the field, and was recognized by President Obama at a White House dinner as a leading entrepreneur in genomic medicine. More recently, she was named to the PharmaVOICE 100 list of the most inspiring people in the life-‐sciences industry. She was recognized for her ability to build bridges across the life-‐science and healthcare industries, bringing people together to harness the power of predictive modeling to change the lives of patients.
Mark Pottle is responsible for the finance, accounting, legal, and human resource functions of GNS Healthcare.
Before joining GNS Healthcare, Mark was CFO of N-of-One Therapeutics, which provides analysis and interpretation of a tumor’s genome so that providers can personalize cancer treatments for patients. Prior to N-of-One, Mark worked at Picis Inc., which provides EMRs for emergency departments, ICUs, and ORs. After Picis was sold to United Healthcare/Optum in 2010, Mark became the CFO of Optum’s Accountable Care Organization division. Mark has also previously worked at several start-up to mid-level companies and has helped raise over $50 million of venture-backed funding, as well as over $150 million in private equity funding.
Mark is also a veteran of the U.S. Army. He graduated from University of New Hampshire with a degree in economics and holds an M.B.A. from Southern New Hampshire University.
Bruce Church is responsible for developing algorithms for REFS™ and leading projects for the development of new products and technologies. Bruce is a member of the founding team of GNS Healthcare.
An expert in statistical physics, machine learning, parallel computing, and causal modeling, Bruce helped develop the original REFS™ platform. Previously, he spent ten years at Cornell University, developing global optimization methods for computational protein folding, the results of which have been published in several peer-reviewed journals.
Bruce has served as the principal investigator on several major grants, including a $2.5 million award from the Department of Energy. He has served on the Board of Directors for U.S. Rugby and coached the under-23 women’s Northeast rugby team. Bruce received a B.S. in applied and engineering physics and a Ph.D. in applied physics from Cornell University.
Gabriel Eichler is responsible for overseeing the growth of GNS’ emerging product solutions portfolio. His focus is primarily on applications of REFS to personalized medicine.
Gabriel has spent most of the last decade working on big-data healthcare applications to opportunities in the pharmaceutical/biotech industry and healthcare care delivery. Formerly he managed several global client programs at PatientsLikeMe focusing on patient-centered research and outcomes. Gabriel was also responsible for establishing that company’s oncology product strategy and portfolio. Prior to PatientsLikeMe, Gabriel worked at Relay Technology Management (acquired by Decision Resources Group), McKinsey and Harvard Medical School.
Gabriel completed his MSc. and PhD in Bioinformatics at Boston University and the National Cancer Institute’s Laboratory of Molecular Pharmacology, jointly. His BSE is in Computer Science from the University of Pennsylvania. He has authored over 30 scholarly manuscripts and book chapters. He is an investor and advisor to numerous early-stage startup companies in the bioinformatics and digital health space. Gabriel also enjoys public speaking and has given over 100 lectures both nationally and internationally on personalized medicine, genomics, patient centricity, open innovation and medical informatics.
Srini Veeravanallur leads the Engineering, Data Services and Information Technology teams that develop our patented REFS and MeasureBase platforms and provide data and IT services.
Prior to GNS, Srini led multiple software development teams and was the Director of R&D at PTC, one of the world’s largest and fastest growing technology companies. Srini has nearly two decades of experience building enterprise applications.
Srini has an M.S. in Computer Science from Boston University, an M.S. in Biomedical Engineering from the Ohio State University, and a B.E. (Hons) in Instrumentation from Birla Institute of Technology & Science, Pilani.
Stacey Wasserman has a proven track record as a senior sales executive with more than 20 years experience in the healthcare technology industry. Currently, Stacey serves as the Vice President of Business Development, Pharmaceutical Market for GNS Healthcare, a leading provider of analytic solutions to pharmaceutical and health plan customers. Prior to that, she was the Senior Sales Director at Activate Networks, which provides a social network analytics platform. Before that, Stacey spent 12 years with Truven Health Analytics (formerly Thomson Reuters) where she was a top performer, selling data and consulting services to pharmaceutical companies. Other former roles include Consultant for Skila and Account Director for IMS Health. Stacey started her career working in Public Relations for Johnson & Johnson.
Outside of work, Stacey lives in Princeton Junction, NJ with her two children and is involved in many local organizations. Stacey holds a B.A. in Biopsychology from the University of Pennsylvania and a M.B.A. from the Rutgers University School of Business.
©GNS Healthcare, 2016